Buy Lorazepam
Online
ATIVAN
(Also known as LORAZEPAM) is
indicated for the management of anxiety disorders or for the
short-term relief of the symptoms of anxiety or anxiety associated
with depressive symptoms.
Medication Information
Adverse reactions, if they occur, are usually observed at
the beginning of therapy and generally disappear on
continued medication or upon decreasing the dose. In a
sample of about 3500 anxious patients, the most frequent
adverse reaction to lorazepam is sedation (15.9%), followed
by dizziness (6.9%), weakness (4.2%), and unsteadiness
(3.4%). Less frequent adverse reactions are disorientation,
depression, nausea, change in appetite, headache, sleep
disturbance, agitation, dermatological symptoms,
eye-function disturbance, together with various
gastrointestinal symptoms and autonomic manifestations. The
incidence of sedation and unsteadiness increased with age.
Small decreases in blood pressure have been noted but are
not clinically significant, probably being related to the
relief of anxiety produced by lorazepam.
Transient amnesia or memory impairment has been reported in
association with the use of benzodiazepines.
Central Nervous System: The most frequent adverse effects
seen with injectable lorazepam are an extension of the
central-nervous-system depressant effects of the drug. The
incidence varied from one study to another, depending on the
dosage, route of administration, use of other
central-nervous-system depressants, and the investigator's
opinion concerning the degree and duration of desired
sedation. Excessive sleepiness and drowsiness were the main
side effects. This interfered with patient cooperation in
approximately 6% (25/446) of patients undergoing regional
blocks or with caudal anesthesia. Patients over 50 years of
age had a higher incidence of excessive sleepiness or
drowsiness when compared with those under 50 (21/106 vs
24/245) when lorazepam was given intravenously (see DOSAGE
AND ADMINISTRATION). On rare occasion (3/1580) the patient
was unable to give personal identification in the operating
room on arrival, an one patient fell when attempting
premature ambulation in the postoperative period.
Symptoms such as restlessness, confusion, depression,
crying, sobbing, and delirium occurred in about 1.3%
(20/1580). One patient injured himself by picking at his
incision during the immediate postoperative period.
Hallucinations were present in about 1% (14/1580) of
patients and were visual and self-limiting.
An occasional patient complained of dizziness, diplopia,
and/or blurred vision. Depressed hearing was infrequently
reported during the peak-effect period.
An occasional patient had a prolonged recovery room stay,
either because of excessive sleepiness or because of some
form of inappropriate behavior. The latter was seen most
commonly when scopolamine was given concomitantly as a
premedicant.
Limited information derived from patients who were
discharged the day after receiving injectable lorazepam
showed one patient complained of some unsteadiness of gait
and a reduced ability to perform complex mental functions.
Enhanced sensitivity to alcoholic beverages has been
reproted more than 24 hours after receiving injectable
lorazepam, similar to experience with other benzodiazepines.
Local Effects: Intramuscular injection of lorazepam has
resulted in pain at the injection site, a sensation of
burning, or observed redness in the same area in a very
variable incidence from one study to another. The overall
incidence of pain and burning was about 17% (146/859) in the
immediate postinjection period and about 1.4% (12/859) at
the 24-hour observation time. Reaction at the injection site
(redness) occurred in approximately 2% (17/859) in the
immediate postinjection period and were present 24 hours
later in about 0.8% (7/859).
Intravenous administration of lorazepam resulted in painful
responses in 13/771 patients or approximately 1.6% in the
immediate postinjection period, and 24 hours later 4/771
patients or about 0.5% still complained of pain. Redness did
not occur immediately following intravenous injection but
was noted in 19/771 patients at the 24-hour observation
period. This incidence is similar to that observed with an
intravenous infusion before lorazepam is given.
Cardiovascular System: Hypertension (0.1%) and hypotension
(0.1%) have occasionally been observed after patients have
received injectable lorazepam.
Respiratory System: Five patients (5/446) who underwent
regional anesthesia were observed to have partial airway
obstruction. This was believed due to excessive sleepiness
at the time of the procedure and resulted in temporary
underventilation. Immediate attention to the airway,
employing the usual countermeasures, will usually suffice to
manage this condition (see also CLINICAL PHARMACOLOGY,
WARNINGS, and PRECAUTIONS). |
